Opinion of the Transparency Council – Treatment of patients with acid sphingomyelinase deficiency (ASMD) type A/B and B
At its meeting on 12 May 2025, the Transparency Council adopted opinion No. 78/2025 on the assessment of changes to the content of the drug program B.158.FM “Treatment of patients with acid sphingomyelinase deficiency (ASMD) type A/B and B (ICD-10: E75.241, E75.244)”